Published in PLoS One on March 09, 2012
PolyQ disease: misfiring of a developmental cell death program? Trends Cell Biol (2012) 0.93
What makes a protein sequence a prion? PLoS Comput Biol (2015) 0.92
Monomeric, oligomeric and polymeric proteins in huntington disease and other diseases of polyglutamine expansion. Brain Sci (2014) 0.84
Effect of mid-infrared free-electron laser irradiation on refolding of amyloid-like fibrils of lysozyme into native form. Protein J (2012) 0.80
Identification of fibrillogenic regions in human triosephosphate isomerase. PeerJ (2016) 0.75
Conformational stability of the RNP domain controls fibril formation of PABPN1. Protein Sci (2015) 0.75
An Intrabody Drug (rAAV6-INT41) Reduces the Binding of N-Terminal Huntingtin Fragment(s) to DNA to Basal Levels in PC12 Cells and Delays Cognitive Loss in the R6/2 Animal Model. J Neurodegener Dis (2016) 0.75
Class A β-lactamases as versatile scaffolds to create hybrid enzymes: applications from basic research to medicine. Biomed Res Int (2013) 0.75
A standard numbering scheme for the class A beta-lactamases. Biochem J (1991) 17.44
Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science (1997) 11.53
Trinucleotide repeat disorders. Annu Rev Neurosci (2007) 9.45
Unfolding free energy changes determined by the linear extrapolation method. 1. Unfolding of phenylmethanesulfonyl alpha-chymotrypsin using different denaturants. Biochemistry (1988) 9.18
Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem (1997) 7.62
Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell (1997) 7.59
Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc Natl Acad Sci U S A (1994) 6.96
Glutamine repeats and neurodegeneration. Annu Rev Neurosci (2000) 6.06
The diversity of the catalytic properties of class A beta-lactamases. Biochem J (1990) 3.98
Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity. J Mol Biol (2001) 2.80
Polyglutamine disruption of the huntingtin exon 1 N terminus triggers a complex aggregation mechanism. Nat Struct Mol Biol (2009) 2.77
Polyglutamine neurodegeneration: protein misfolding revisited. Trends Neurosci (2008) 2.63
Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature (2003) 2.60
Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. Hum Mol Genet (2002) 2.44
Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. Nat Genet (1998) 2.42
Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. Hum Mol Genet (1998) 2.39
A toxic monomeric conformer of the polyglutamine protein. Nat Struct Mol Biol (2007) 2.33
Single-domain antibody fragments with high conformational stability. Protein Sci (2002) 2.31
Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. Acc Chem Res (2005) 2.25
Oligoproline effects on polyglutamine conformation and aggregation. J Mol Biol (2005) 2.14
Ectopically expressed CAG repeats cause intranuclear inclusions and a progressive late onset neurological phenotype in the mouse. Cell (1997) 2.13
Fluorescence correlation spectroscopy shows that monomeric polyglutamine molecules form collapsed structures in aqueous solutions. Proc Natl Acad Sci U S A (2006) 2.00
Secondary structure of Huntingtin amino-terminal region. Structure (2009) 1.98
Measuring and increasing protein stability. Trends Biotechnol (1990) 1.95
Glutamine, alanine or glycine repeats inserted into the loop of a protein have minimal effects on stability and folding rates. J Mol Biol (1997) 1.94
Intranuclear neuronal inclusions: a common pathogenic mechanism for glutamine-repeat neurodegenerative diseases? Neuron (1997) 1.91
Peptide models for inherited neurodegenerative disorders: conformation and aggregation properties of long polyglutamine peptides with and without interruptions. FEBS Lett (1999) 1.83
Beta-lactamase of Bacillus licheniformis 749/C. Refinement at 2 A resolution and analysis of hydration. J Mol Biol (1991) 1.79
Solution structure of polyglutamine tracts in GST-polyglutamine fusion proteins. FEBS Lett (2002) 1.78
A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme. Nature (2003) 1.66
The two-stage pathway of ataxin-3 fibrillogenesis involves a polyglutamine-independent step. J Biol Chem (2006) 1.66
Soluble polyglutamine oligomers formed prior to inclusion body formation are cytotoxic. Hum Mol Genet (2007) 1.66
A linear lattice model for polyglutamine in CAG-expansion diseases. Proc Natl Acad Sci U S A (2002) 1.62
Flanking polyproline sequences inhibit beta-sheet structure in polyglutamine segments by inducing PPII-like helix structure. J Mol Biol (2007) 1.59
Quantitative characterization of intrinsic disorder in polyglutamine: insights from analysis based on polymer theories. Biophys J (2007) 1.53
X-ray fiber diffraction of amyloid fibrils. Methods Enzymol (1999) 1.45
Extended polyglutamine tracts cause aggregation and structural perturbation of an adjacent beta barrel protein. J Biol Chem (2006) 1.37
Pathogenic and non-pathogenic polyglutamine tracts have similar structural properties: towards a length-dependent toxicity gradient. J Mol Biol (2007) 1.31
Mechanisms of ataxin-3 misfolding and fibril formation: kinetic analysis of a disease-associated polyglutamine protein. J Mol Biol (2007) 1.29
Tracking mutant huntingtin aggregation kinetics in cells reveals three major populations that include an invariant oligomer pool. J Biol Chem (2010) 1.28
In-cell aggregation of a polyglutamine-containing chimera is a multistep process initiated by the flanking sequence. J Biol Chem (2007) 1.19
Polyglutamine induced misfolding of huntingtin exon1 is modulated by the flanking sequences. PLoS Comput Biol (2010) 1.17
The interplay between PolyQ and protein context delays aggregation by forming a reservoir of protofibrils. PLoS One (2006) 1.15
Amino acid sequences flanking polyglutamine stretches influence their potential for aggregate formation. Neuroreport (2001) 1.10
The non-core regions of human lysozyme amyloid fibrils influence cytotoxicity. J Mol Biol (2010) 1.07
Towards the treatment of polyglutamine diseases: the modulatory role of protein context. Curr Med Chem (2010) 1.05
Biochemical, ultrastructural, and reversibility studies on huntingtin filaments isolated from mouse and human brain. J Neurosci (2004) 1.04
Normal and aberrant biological self-assembly: Insights from studies of human lysozyme and its amyloidogenic variants. Acc Chem Res (2006) 1.04
Intra- and intermolecular beta-pleated sheet formation in glutamine-repeat inserted myoglobin as a model for polyglutamine diseases. J Biol Chem (2001) 1.02
Formation of morphologically similar globular aggregates from diverse aggregation-prone proteins in mammalian cells. Proc Natl Acad Sci U S A (2005) 1.00
The neuropathology of CAG repeat diseases: review and update of genetic and molecular features. Brain Pathol (1997) 0.99
In vitro synthesis and cloning of long CAG repeats. Biotechniques (1996) 0.99
The structural impact of a polyglutamine tract is location-dependent. Biophys J (2008) 0.93
Flanking domain stability modulates the aggregation kinetics of a polyglutamine disease protein. Protein Sci (2011) 0.93
Aggregation of truncated GST-HD exon 1 fusion proteins containing normal range and expanded glutamine repeats. Philos Trans R Soc Lond B Biol Sci (1999) 0.90
The zinc center influences the redox and thermodynamic properties of Escherichia coli thioredoxin 2. J Mol Biol (2008) 0.88
The Bacillus licheniformis BlaP beta-lactamase as a model protein scaffold to study the insertion of protein fragments. Protein Sci (2007) 0.86
The rate of polyQ-mediated aggregation is dramatically affected by the number and location of surrounding domains. J Mol Biol (2011) 0.82
Rapid and easy development of versatile tools to study protein/ligand interactions. Protein Eng Des Sel (2008) 0.80
[Sequential Edman degredation]. Biochimie (1977) 0.79
Location trumps length: polyglutamine-mediated changes in folding and aggregation of a host protein. Biophys J (2011) 0.78
A strategy for generating polyglutamine 'length libraries' in model host proteins. Protein Eng Des Sel (2008) 0.77
Folding of class A beta-lactamases is rate-limited by peptide bond isomerization and occurs via parallel pathways. Biochemistry (2010) 0.76
Update of the standard numbering scheme for class B beta-lactamases. Antimicrob Agents Chemother (2004) 2.83
Metallo-beta-lactamases as emerging resistance determinants in Gram-negative pathogens: open issues. Int J Antimicrob Agents (2007) 2.61
On functional and structural heterogeneity of VIM-type metallo-beta-lactamases. J Antimicrob Chemother (2003) 2.47
A metallo-beta-lactamase enzyme in action: crystal structures of the monozinc carbapenemase CphA and its complex with biapenem. J Mol Biol (2005) 1.78
Chromosome-encoded CTX-M-3 from Kluyvera ascorbata: a possible origin of plasmid-borne CTX-M-1-derived cefotaximases. Antimicrob Agents Chemother (2004) 1.76
A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme. Nature (2003) 1.66
CAU-1, a subclass B3 metallo-beta-lactamase of low substrate affinity encoded by an ortholog present in the Caulobacter crescentus chromosome. Antimicrob Agents Chemother (2002) 1.52
Current challenges in antimicrobial chemotherapy: focus on ß-lactamase inhibition. Drugs (2010) 1.50
Identification of a universal VHH framework to graft non-canonical antigen-binding loops of camel single-domain antibodies. J Mol Biol (2005) 1.41
The 1.5-A structure of Chryseobacterium meningosepticum zinc beta-lactamase in complex with the inhibitor, D-captopril. J Biol Chem (2003) 1.35
Crystal structure of extended-spectrum beta-lactamase Toho-1: insights into the molecular mechanism for catalytic reaction and substrate specificity expansion. Biochemistry (2003) 1.34
Analysis of the importance of the metallo-beta-lactamase active site loop in substrate binding and catalysis. Chem Biol (2003) 1.32
Structural basis for the broad-spectrum inhibition of metallo-beta-lactamases by thiols. Org Biomol Chem (2008) 1.26
Kinetic properties of four plasmid-mediated AmpC beta-lactamases. Antimicrob Agents Chemother (2005) 1.21
Crystal structure and activity of Bacillus subtilis YoaJ (EXLX1), a bacterial expansin that promotes root colonization. Proc Natl Acad Sci U S A (2008) 1.19
Description of In116, the first blaCTX-M-2-containing complex class 1 integron found in Morganella morganii isolates from Buenos Aires, Argentina. J Antimicrob Chemother (2005) 1.17
Identification of the core structure of lysozyme amyloid fibrils by proteolysis. J Mol Biol (2006) 1.17
Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding. Antimicrob Agents Chemother (2010) 1.16
Biochemical and structural characterization of the subclass B1 metallo-β-lactamase VIM-4. Antimicrob Agents Chemother (2010) 1.16
The structure of the dizinc subclass B2 metallo-beta-lactamase CphA reveals that the second inhibitory zinc ion binds in the histidine site. Antimicrob Agents Chemother (2009) 1.14
Substrate-activated zinc binding of metallo-beta -lactamases: physiological importance of mononuclear enzymes. J Biol Chem (2002) 1.13
The extracellular chaperone clusterin potently inhibits human lysozyme amyloid formation by interacting with prefibrillar species. J Mol Biol (2007) 1.10
Structure and properties of a complex of α-synuclein and a single-domain camelid antibody. J Mol Biol (2010) 1.09
Critical role of tryptophan 154 for the activity and stability of class D beta-lactamases. Biochemistry (2009) 1.08
Is it necessary to change the classification of {beta}-lactamases? J Antimicrob Chemother (2005) 1.07
The non-core regions of human lysozyme amyloid fibrils influence cytotoxicity. J Mol Biol (2010) 1.07
OXA-198, an acquired carbapenem-hydrolyzing class D beta-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother (2011) 1.07
Advantages and drawbacks of nanospray for studying noncovalent protein-DNA complexes by mass spectrometry. Rapid Commun Mass Spectrom (2002) 1.06
From dormant to germinating spores of Streptomyces coelicolor A3(2): new perspectives from the crp null mutant. J Proteome Res (2005) 1.05
Three factors that modulate the activity of class D β-lactamases and interfere with the post-translational carboxylation of Lys70. Biochem J (2010) 1.03
Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries. Bioorg Med Chem (2009) 1.02
Development of a chitosan nanofibrillar scaffold for skin repair and regeneration. Biomacromolecules (2011) 1.02
Identification of bla(IMP-22) in Pseudomonas spp. in urban wastewater and nosocomial environments: biochemical characterization of a new IMP metallo-enzyme variant and its genetic location. J Antimicrob Chemother (2009) 1.01
Biochemical and molecular characterization of three new variants of AmpC beta-lactamases from Morganella morganii. Antimicrob Agents Chemother (2006) 1.01
Engineering a camelid antibody fragment that binds to the active site of human lysozyme and inhibits its conversion into amyloid fibrils. Biochemistry (2008) 1.00
Polyolefin matrixes with permanent antibacterial activity: preparation, antibacterial activity, and action mode of the active species. Biomacromolecules (2006) 1.00
Mutational analysis of the two zinc-binding sites of the Bacillus cereus 569/H/9 metallo-beta-lactamase. Biochem J (2002) 1.00
Impact of the native-state stability of human lysozyme variants on protein secretion by Pichia pastoris. FEBS J (2006) 0.99
New integrative method to generate Bacillus subtilis recombinant strains free of selection markers. Appl Environ Microbiol (2004) 0.99
Mutational analysis of the zinc- and substrate-binding sites in the CphA metallo-beta-lactamase from Aeromonas hydrophila. Biochem J (2008) 0.99
Insights into bacterial cellulose biosynthesis by functional metagenomics on Antarctic soil samples. ISME J (2009) 0.95
Probing the specificity of the subclass B3 FEZ-1 metallo-beta-lactamase by site-directed mutagenesis. J Biol Chem (2004) 0.95
Mercaptophosphonate compounds as broad-spectrum inhibitors of the metallo-beta-lactamases. J Med Chem (2010) 0.95
Rationalising lysozyme amyloidosis: insights from the structure and solution dynamics of T70N lysozyme. J Mol Biol (2005) 0.94
A non-natural variant of human lysozyme (I59T) mimics the in vitro behaviour of the I56T variant that is responsible for a form of familial amyloidosis. Protein Eng Des Sel (2010) 0.93
A tripeptide deletion in the R2 loop of the class C beta-lactamase enzyme FOX-4 impairs cefoxitin hydrolysis and slightly increases susceptibility to beta-lactamase inhibitors. J Antimicrob Chemother (2010) 0.93
Characterization of oligomeric species on the aggregation pathway of human lysozyme. J Mol Biol (2009) 0.93
Dramatic broadening of the substrate profile of the Aeromonas hydrophila CphA metallo-beta-lactamase by site-directed mutagenesis. J Biol Chem (2005) 0.93
Escherichia coli fusion carrier proteins act as solubilizing agents for recombinant uncoupling protein 1 through interactions with GroEL. Biochem Biophys Res Commun (2005) 0.92
Overproduction and biochemical characterization of the Chryseobacterium meningosepticum BlaB metallo-beta-lactamase. Antimicrob Agents Chemother (2002) 0.92
Biochemical characterisation of the CTX-M-14 beta-lactamase. Int J Antimicrob Agents (2007) 0.92
Local cooperativity in an amyloidogenic state of human lysozyme observed at atomic resolution. J Am Chem Soc (2010) 0.91
A detailed kinetic study of Mox-1, a plasmid-encoded class C beta-lactamase. FEMS Microbiol Lett (2003) 0.91
Solution structural study of BlaI: implications for the repression of genes involved in beta-lactam antibiotic resistance. J Mol Biol (2003) 0.91
Dynamic combinatorial mass spectrometry leads to metallo-beta-lactamase inhibitors. J Med Chem (2008) 0.90
Crystal structure of the Mycobacterium fortuitum class A beta-lactamase: structural basis for broad substrate specificity. Antimicrob Agents Chemother (2006) 0.90
Activation of innate immunity by lysozyme fibrils is critically dependent on cross-β sheet structure. Cell Mol Life Sci (2013) 0.90
The zinc center influences the redox and thermodynamic properties of Escherichia coli thioredoxin 2. J Mol Biol (2008) 0.88
Disulfide bonds reduce the toxicity of the amyloid fibrils formed by an extracellular protein. Angew Chem Int Ed Engl (2011) 0.88
Disease-related amyloidogenic variants of human lysozyme trigger the unfolded protein response and disturb eye development in Drosophila melanogaster. FASEB J (2011) 0.87
Distant and new mutations in CTX-M-1 beta-lactamase affect cefotaxime hydrolysis. Antimicrob Agents Chemother (2011) 0.87
Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli. Antimicrob Agents Chemother (2008) 0.87
Kinetic and crystallographic studies of extended-spectrum GES-11, GES-12, and GES-14 β-lactamases. Antimicrob Agents Chemother (2012) 0.87
The Bacillus licheniformis BlaP beta-lactamase as a model protein scaffold to study the insertion of protein fragments. Protein Sci (2007) 0.86
Broad antibiotic resistance profile of the subclass B3 metallo-β-lactamase GOB-1, a di-zinc enzyme. FEBS J (2011) 0.86
Positively cooperative binding of zinc ions to Bacillus cereus 569/H/9 beta-lactamase II suggests that the binuclear enzyme is the only relevant form for catalysis. J Mol Biol (2009) 0.86
Creating hybrid proteins by insertion of exogenous peptides into permissive sites of a class A beta-lactamase. FEBS J (2008) 0.85
The inhibition of metallo-beta-lactamase by thioxo-cephalosporin derivatives. Bioorg Med Chem Lett (2004) 0.84
Characterisation of KLUA-9, a beta-lactamase from extended-spectrum cephalosporin-susceptible Kluyvera ascorbata, and genetic organisation of bla(KLUA-9). Int J Antimicrob Agents (2006) 0.84
Clonal diversity and metallo-beta-lactamase production in clinical isolates of Stenotrophomonas maltophilia. Microb Drug Resist (2002) 0.84
DNA vaccination for the priming of neutralizing antibodies against non-immunogenic STa enterotoxin from enterotoxigenic Escherichia coli. Vaccine (2005) 0.83
Exploring the Antarctic soil metagenome as a source of novel cold-adapted enzymes and genetic mobile elements. Rev Argent Microbiol (2011) 0.83
The in-vitro antimicrobial activity of some medicinal plants against beta-lactam-resistant bacteria. J Infect Dev Ctries (2009) 0.83
Use of red autofluorescence for monitoring prodiginine biosynthesis. J Microbiol Methods (2013) 0.83
TEM-1 beta-lactamase folds in a nonhierarchical manner with transient non-native interactions involving the C-terminal region. Biochemistry (2008) 0.83
Inhibitors of the FEZ-1 metallo-beta-lactamase. Bioorg Med Chem Lett (2006) 0.82
A novel extended-spectrum TEM-type beta-lactamase, TEM-138, from Salmonella enterica serovar Infantis. Antimicrob Agents Chemother (2006) 0.82
Octarellin VI: using rosetta to design a putative artificial (β/α)8 protein. PLoS One (2013) 0.82
Relationship between propeptide pH unfolding and inhibitory ability during ProDer p 1 activation mechanism. J Mol Biol (2007) 0.82
Secondary-structure characterization by far-UV CD of highly purified uncoupling protein 1 expressed in yeast. Biochem J (2004) 0.82
Novel chromosome-encoded CTX-M-78 beta-lactamase from a Kluyvera georgiana clinical isolate as a putative origin of CTX-M-25 subgroup. Antimicrob Agents Chemother (2010) 0.81
Use of bifunctional hybrid beta-lactamases for epitope mapping and immunoassay development. J Immunol Methods (2007) 0.81
R164H and V240H replacements by site-directed mutagenesis of TEM-149 extended-spectrum β-lactamase: kinetic analysis of TEM-149H240 and TEM-149H164-H240 laboratory mutants. Antimicrob Agents Chemother (2012) 0.81
Synthesis of copolymer brushes endowed with adhesion to stainless steel surfaces and antibacterial properties by controlled nitroxide-mediated radical polymerization. Langmuir (2004) 0.81
Synthesis and evaluation of N1/C4-substituted beta-lactams as PPE and HLE inhibitors. Bioorg Med Chem (2004) 0.81
Activation mechanism of recombinant Der p 3 allergen zymogen: contribution of cysteine protease Der p 1 and effect of propeptide glycosylation. J Biol Chem (2008) 0.81
Comparative functional analysis of the human macrophage chitotriosidase. Protein Sci (2011) 0.81